Effect of GLP-1 receptor agonists on prostate cancer risk reduction: a systematic review and meta-analysis
The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
Background Prostate cancer is one of the most prevalent malignancies among men globally. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs), primarily used for type 2 diabetes mellitus (T2DM) management, have been investigated for their potential effects on cancer risks. This systematic review and meta-analysis aimed to assess the association between GLP-1 RA use and risk reduction of prostate cancer. Methods A comprehensive literature search was conducted across PubMed, Embase, and Web of Science up to July 30, 2024. Studies that met the inclusion criteria randomized controlled trials, cohort studies, case-control studies, and observational studies assessing the incidence of prostate cancer in GLP-1 RA-treated patients were included. The quality of studies was evaluated using the Newcastle-Ottawa Scale and the Cochrane Risk of Bias tool. Meta-analysis was performed using a random effects model. Results A total of five studies were included, analyzing data from diverse international contexts. The included studies showed a reduced risk of prostate cancer with both adjusted and unadjusted effect estimates with GLP-1 RAs. The meta-analysis revealed an RR of 0.72 (95% CI: 0.610 to 0.832), indicating a statistically significant 28% reduction in prostate cancer risk associated with GLP-1 RA use compared to placebo or other antidiabetic drugs. Moderate heterogeneity was observed (I 2 = 51%). Sensitivity analysis confirmed the results. Conclusion The findings suggest a significant…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Dual and triple agonists such as glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide (GLP-1/GIP) or GLP-1/GIP/glucagon receptor agonists have demonstrated superior efficacy in reducing body weight, improving glycemic control, and enhancing lipid metabolism compared to traditional monotherapies.9”
From The Triple‐Agonist Revolution: Retatrutide and the Paradigm Shift in Multi‐Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities (2026) · cites this paper as [9]
Citations
Cites
Karantanos, T., Corn, P. G., & Thompson, T. C. (2013) · Oncogene · doi:10.1038/onc.2013.206 · Cited by 866
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
Diabetes mellitus and risk of prostate cancer: a meta-analysis
Bonovas, S., Filioussi, K., & Tsantes, A. (2004) · Diabetologia · doi:10.1007/s00125-004-1415-6 · Cited by 327
Diabetes and Cancer: Risk, Challenges, Management and Outcomes
Shahid, R. K., Ahmed, S., Le, D., & Yadav, S. (2021) · Cancers · doi:10.3390/cancers13225735 · Cited by 187 · cited 1×
“The intersection of diabetes and prostate cancer is particularly complex, as epidemiological studies suggest that diabetes may be associated with a lower risk of prostate cancer [9, 10].”
Diabetes and Risk of Prostate Cancer in a Prospective Cohort of US Men
Rodriguez, C. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwh334 · Cited by 184
Exendin-4, a GLP-1 Receptor Agonist, Attenuates Prostate Cancer Growth
Nomiyama, T., Kawanami, T., Irie, S., Hamaguchi, Y., Terawaki, Y., Murase, K., Tsutsumi, Y., Nagaishi, R., Tanabe, M., Morinaga, H., et al. (2014) · Diabetes · doi:10.2337/db13-1169 · Cited by 136
Silverii, G. A., Monami, M., Gallo, M., Ragni, A., Prattichizzo, F., Renzelli, V., Ceriello, A., & Mannucci, E. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15382 · Cited by 113
Nauck, M. A., Jensen, T. J., Rosenkilde, C., Calanna, S., Buse, J. B., & the LEADER Publication Committee on behalf of the LEADER Trial Investigators (2018) · Diabetes Care · doi:10.2337/dc17-1825 · Cited by 94
Diabetes Mellitus and Prostate Cancer Risk; A Nationwide Case–Control Study within PCBaSe Sweden
Fall, K., Garmo, H., Gudbjörnsdottir, S., Stattin, P., & Zethelius, B. (2013) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-12-1046 · Cited by 75
Wang, J., & Kim, C. H. (2022) · Endocrine Research · doi:10.1080/07435800.2021.1955255 · Cited by 74
Research works printed but not linked: 4
- De Ycaza AE, Brito JP, McCoy RG, Shao H, Singh Ospina N (2024) Glucagon-like peptide-1 receptor agonists and thyroid cancer: a narrative review. Thyroid. 34(4):403–18
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 372:1
- Skriver C, Friis S, Knudsen LB, Catarig AM, Clark AJ, Dehlendorff C, Mørch LS (2023) Potential preventive properties of GLP-1 receptor agonists against prostate cancer: a nationwide cohort study. Diabetologia 66(11):2007–2016 · DOI
- Stein MS, Kalff V, Williams SG, Murphy DG, Colman PG, Hofman MS (2024) The GLP-1 receptor is expressed in vivo by human metastatic prostate cancer. Endocr Oncol. 4:1
Cited by
GLP ‐1 receptor agonists and the risk for cancer: A meta‐analysis of randomized controlled trials
Silverii, G. A., Marinelli, C., Bettarini, C., Del Vescovo, G. G., Monami, M., & Mannucci, E. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16489 · Cited by 67
“Longer-term observations on cohorts of patients treated with GLP-1RA reported significant reductions in the risk of some obesity-related malignancies, such as prostate 28,74 and colorectal 21,28 cancer, which were not detected in clinical trials.”
Valencia-Rincón, E., Rai, R., Chandra, V., & Wellberg, E. A. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194743 · Cited by 43
Daou, C. A. Z., Hosn, O. A., Ghzayel, L., & Mourad, M. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70038 · Cited by 25
Hung, C., Zeng, B., Hsu, C.-W., Chen, P., Sun, C., Carvalho, A. F., Stubbs, B., Chen, Y., Chen, T., Lei, W., et al. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000003450 · Cited by 20
Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown
Mannucci, E., & Dicembrini, I. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01135-0 · Cited by 16
Metadata
- Authors
- Sharma, N., Khatib, M. N., Balaraman, A. K., Roopashree, R., Kaur, M., Srivastava, M., Barwal, A., Prasad, G. V. S., Rajput, P., Syed, R., Sharma, G., Kumar, S., Singh, M. P., Bushi, G., Chilakam, N., Pandey, S., Brar, M., Mehta, R., Sah, S., Gaidhane, A. M., & Shabil, M.
- Affiliations
- National Institute of Pharmaceutical Education and Research (IN)
- Datta Meghe Institute of Higher Education and Research (IN)
- University of Cyberjaya (MY)
- Jain University (IN)
- Vivekananda Global University (IN)
- NIMS University (IN)
- Chandigarh University (IN)
- Uttaranchal University (IN)
- Graphic Era University (IN)
- Saveetha University (IN)
- Lovely Professional University (IN)
- Noida Institute of Engineering and Technology Pharmacy Institute (IN)
- Chitkara University (IN)
- Manav Rachna International Institute of Research and Studies (IN)
- Dr. D. Y. Patil Medical College, Hospital and Research Centre (IN)
- Corresponding author
- Shabil, Muhammed
- ORCID
- Venue
- International Urology and Nephrology
- Published
- 2024-11-04
- Volume
- 57
- Issue
- 4
- Pages
- 1039-1049
- ISSN
- 0301-1623 (ISSN-L)
- 1573-2584
- OpenAlex
- W4404026896
- Semantic Scholar
- 8ecafaef396ae315cd892d2a7118536d5b81198e
- Cited by
- 21
- References
- 26
- Citations by year
- 2026: 10 · 2025: 10 · 2024: 1
- FWCI
- 0.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- International Urology and Nephrology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Keywords
- GLP-1 receptor agonists, prostate cancer, cancer risk reduction, type 2 diabetes, antidiabetic drugs, chemoprevention, drug repurposing
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Male, Prostatic Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of GLP-1 receptor agonists on prostate cancer risk reduction: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1007/s11255-024-04266-4
- The paper
- Sharma, N., Khatib, M. N., Balaraman, A. K., Roopashree, R., Kaur, M., Srivastava, M., Barwal, A., Prasad, G. V. S., Rajput, P., Syed, R., Sharma, G., Kumar, S., Singh, M. P., Bushi, G., Chilakam, N., Pandey, S., Brar, M., Mehta, R., Sah, S., . . . Shabil, M. (2024). Effect of GLP-1 receptor agonists on prostate cancer risk reduction: a systematic review and meta-analysis. International Urology and Nephrology. https://doi.org/10.1007/s11255-024-04266-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.